Article info
PDFPostScript
Letter
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation
- Correspondence to Prof Laurent Peyrin-Biroulet, Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Lorraine 54 511, France; peyrinbiroulet{at}gmail.com
Citation
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation
Publication history
- Received November 29, 2017
- Revised December 23, 2017
- Accepted December 29, 2017
- First published January 13, 2018.
Online issue publication
June 15, 2020
Article Versions
- Previous version (15 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.